Safety of BTDS in Subjects With Low Back Pain: A 52-Week Extension Phase of BUP3015

August 27, 2012 updated by: Purdue Pharma LP

A Multicenter, Randomized, Double-blind, Active Comparator Study to Determine the Efficacy and Safety of BTDS 20 or Oxycodone Immediate-Release Vs Buprenorphine Transdermal System (BTDS) 5 in Subjects With Moderate to Severe Low Back Pain: A 52-Week Open-label Extension Phase of BUP3015

The purpose of the extension phase is to evaluate the long-term safety and tolerability of buprenorphine transdermal system (BTDS). Subjects begin the extension phase on BTDS 5 mcg/h and may up- or down-titrate the dose [up to BTDS 20 micrograms (mcg) / hour (h)] depending on adequate pain relief and tolerability.

Study Overview

Status

Terminated

Conditions

Intervention / Treatment

Detailed Description

Buprenorphine is a synthetic opioid analgesic with over 25 years of international clinical experience indicating it to be safe and effective in a variety of therapeutic situations for the relief of moderate to severe pain.

Study Type

Interventional

Enrollment (Actual)

354

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Alabama
      • Birmingham, Alabama, United States, 35244
        • Birmingham Pain Center
      • Birmingham, Alabama, United States, 35249
        • Arthritis Clinical Intervention Program
      • Haleyville, Alabama, United States, 35565
        • Winston Physician Services, Inc
    • Arizona
      • Phoenix, Arizona, United States, 85023
        • Arizona Research Center Inc
      • Phoenix, Arizona, United States, 85029
        • Radiant Research
      • Tucson, Arizona, United States, 85712
        • Advanced Clinical Therapeutics
    • Arkansas
      • Hot Springs, Arkansas, United States, 71913
        • Hot Springs Pain Clinic
    • California
      • Anaheim, California, United States, 92805
        • NuLife Clinical Research, Inc.
      • Beverly Hills, California, United States, 90211
        • Lovelace Scientific Resources
      • Carmichael, California, United States, 95608
        • Northern California Research Corp
      • Chula Vista, California, United States, 91911
        • International Clinical Research Network
      • Fountain Valley, California, United States, 92708
        • Shreenath Clinical Service
      • Sacramento, California, United States, 95817
        • U of Calif at Davis, Med Ctr, Pain Management Center
      • San Diego, California, United States, 92108
        • Accelovance
    • Colorado
      • Pueblo, Colorado, United States, 81008
        • Southern Colorado Clinic
    • Florida
      • Chiefland, Florida, United States, 32626
        • Chiefland Medical Center
      • Deland, Florida, United States, 32720
        • University Clinical Research Deland
      • Jupiter, Florida, United States, 33458
        • Drug Study Institute
      • Largo, Florida, United States, 33770
        • Innovative Research of West Florida, Inc.
      • Ocala, Florida, United States, 34471
        • Renstar Medical
      • Ormond Beach, Florida, United States, 32174
        • Peninsula Research Inc.
      • Palm Harbor, Florida, United States, 34684
        • The Arthritis Center
      • Pembroke Pines, Florida, United States, 33024
        • University Clinical Research, Inc.
      • Plantation, Florida, United States, 33324
        • Gold Coast Research, LLC
      • West Palm Beach, Florida, United States, 33409
        • Palm Beach Research Center
    • Georgia
      • Marietta, Georgia, United States, 30060
        • Georgia Medical Research Institute
      • Stockbridge, Georgia, United States, 30281
        • Atlanta Knee & Shoulder Clinic
    • Idaho
      • Boise, Idaho, United States, 83702
        • Pain Care Boise
      • Meridian, Idaho, United States, 83742
        • Idaho Arthritis and Osteoporosis Center
    • Illinois
      • Chicago, Illinois, United States, 60610
        • Pain and Rehabilitation Clinic of Chicago
    • Indiana
      • Evansville, Indiana, United States, 47714
        • MediSphere Medical Research Center, LLC
      • Evansville, Indiana, United States, 47714
        • GFI Research Center
    • Iowa
      • Dubuque, Iowa, United States, 52002
        • Medical Associates Clinics
    • Kansas
      • Overland Park, Kansas, United States, 66211
        • Vince and Associates Clinical Research
      • Prairie Village, Kansas, United States, 66206
        • Ctt, Inc.
    • Kentucky
      • Madisonville, Kentucky, United States, 42431
        • Commonwealth Biomedical Research, LLC
    • Louisiana
      • Metairie, Louisiana, United States, 70006
        • New Orleans Clinical Trial Management Inc.
      • New Orleans, Louisiana, United States, 70114
        • Louisiana Research Associates, Inc.
      • New Orleans, Louisiana, United States, 70115
        • Best Clinical Trials, LLC
      • New Orleans, Louisiana, United States, 70115
        • Research Center of Louisiana
    • Maryland
      • Baltimore, Maryland, United States, 21215
        • Sinai Hospital of Baltimore
    • Massachusetts
      • Springfield, Massachusetts, United States, 01103
        • Future Care Studies
    • Michigan
      • Kalamazoo, Michigan, United States, 49009
        • Rheumatology Pc
      • Saint Joseph, Michigan, United States, 49085
        • Lake Michigan Clinical Research & Consulting, Inc.
    • Missouri
      • St Louis, Missouri, United States, 63108
        • Medex Healthcare Research Inc
      • St Louis, Missouri, United States, 63141
        • HealthCare Research
    • Nebraska
      • Omaha, Nebraska, United States, 68134
        • Meridian Clinical Research, LLC
    • Nevada
      • Henderson, Nevada, United States, 89014
        • Lovelace Scientific Resources
      • North Las Vegas, Nevada, United States, 89030
        • Pivotal Research Centers
    • New York
      • New York, New York, United States, 10022
        • Research Across America
    • North Carolina
      • Charlotte, North Carolina, United States, 28207
        • Pain and Orthopedic Neurology , Charlotte Spine Center,
      • Charlotte, North Carolina, United States, 28209
        • Metrolina Medical Research
      • Durham, North Carolina, United States, 27704
        • Triangle Orthopaedic Associates
      • Greensboro, North Carolina, United States, 27401
        • PharmQuest
      • Morgantown, North Carolina, United States, 28655
        • Medark Clinical Research
      • Raleigh, North Carolina, United States, 27612
        • Wake Research Associates, LLC
      • Winston Salem, North Carolina, United States, 27103
        • Center for Clinical Research
    • North Dakota
      • Bismark, North Dakota, United States, 58502
        • Odyssey Research
    • Oklahoma
      • Oklahoma City, Oklahoma, United States, 73103
        • COR Clinical Research, LLC
      • Oklahoma City, Oklahoma, United States, 73112
        • Associated Medical Services Inc
    • Pennsylvania
      • Altoona, Pennsylvania, United States, 16602
        • Keystone Clinical Research
      • Bethlehem, Pennsylvania, United States, 18016
        • Valley Pain Specialists
      • Duncansville, Pennsylvania, United States, 16635
        • Altoona Center for Clinical Research
      • Mechanicsburg, Pennsylvania, United States, 17055
        • Central Pennsylvania Clinical Research
      • Shippensburg, Pennsylvania, United States, 17257
        • BioMedical Research Associates
      • State College, Pennsylvania, United States, 16801
        • University Orthopedics Center
    • Rhode Island
      • Cranston, Rhode Island, United States, 29200
        • New England Center Clinical Research
      • Warwick, Rhode Island, United States, 02886
        • Omega Medical Research
    • South Carolina
      • Orangeburg, South Carolina, United States, 29118
        • The Arthritis and Osteoporosis Center
    • South Dakota
      • Watertown, South Dakota, United States, 57201
        • Brown Clinic
    • Tennessee
      • Bristol, Tennessee, United States, 37620
        • Holston Medical Group
      • Bristol, Tennessee, United States, 37620
        • Tri Cities Medical Research
      • Kingsport, Tennessee, United States, 37660
        • Holston Medical Group
    • Texas
      • Dallas, Texas, United States, 75251
        • Galenos Research
      • Fort Worth, Texas, United States, 76135
        • Benchmark Research
      • Harker Heights, Texas, United States, 76548
        • Team Research of Central Texas
      • Richardson, Texas, United States, 75080
        • KRK Medical Research
      • San Angelo, Texas, United States, 76904
        • Benchmark Research
      • San Antonio, Texas, United States, 78233
        • Unlimited Research
      • San Antonio, Texas, United States, 78238
        • Texas Medical Research Associates
      • Spring, Texas, United States, 77386
        • Clinical Trial Network Oaks Medical Center
      • Wichita Falls, Texas, United States, 76301
        • N. Texas Neuro Research
    • Utah
      • Salt Lake City, Utah, United States, 84106
        • Lifetree Clinical Research
    • Wisconsin
      • Oregon, Wisconsin, United States, 53575
        • Dean Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Subjects who completed all visits of the double-blind phase on study drug, and subjects who discontinued study drug due to lack of therapeutic effect in the double-blind phase but completed all visits of the double-blind phase off study drug are eligible to enroll in the extension phase.
  • For subjects entering the extension, 4 electrocardiograms (ECGs) are required at entry if none were collected prior to randomization while on BTDS 20. NOTE: Subjects with any 1 QT data corrected for heart rate using the Fridericia formula (QTcF) interval ≥ 500 milliseconds (msec) would be discontinued from the extension phase

Exclusion Criteria:

  • Subjects requiring long-acting opioid analgesics [once- or twice-daily dosing with a every (q) 24 hours (h) or q12h drug] or transdermal fentanyl during the extension phase should be discontinued from the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: BTDS
Buprenorphine transdermal patch
Drug: Buprenorphine transdermal patch
Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear.
Other Names:
  • Butrans™
Drug: Buprenorphine transdermal patch
Buprenorphine transdermal patch 10 mcg/h applied for 7-day wear.
Other Names:
  • Butrans™
Drug: Buprenorphine transdermal patch
Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear.
Other Names:
  • Butrans™

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of Participants With Adverse Events (AEs) as a Measure of Safety
Time Frame: 52-week extension phase
The purpose of the extension phase was to evaluate the long-term safety and tolerability of BTDS in subjects who had participated in the core study (BUP3015).
52-week extension phase

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Purdue Pharma LP

Investigators

  • Study Director: Deborah L Steiner, MD, MS, Purdue Pharma LP

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

June 1, 2004

Primary Completion (Actual)

September 1, 2005

Study Completion (Actual)

January 1, 2008

Study Registration Dates

First Submitted

May 17, 2010

First Submitted That Met QC Criteria

May 18, 2010

First Posted (Estimate)

May 19, 2010

Study Record Updates

Last Update Posted (Estimate)

September 3, 2012

Last Update Submitted That Met QC Criteria

August 27, 2012

Last Verified

August 1, 2012

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • BUP3015S

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Back Pain Lower Back Chronic

Clinical Trials on Buprenorphine transdermal patch

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kyrgyzstan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe